MORE HERE:
While more than half of the U.S. population has had at least one COVID-19 vaccine dose, less than 1 percent of people in the developing world have had one shot, according to Our World In Data.
Novavax’s study involved nearly 30,000 people ages 18 and up in the U.S. and Mexico. Two-thirds received two doses of the vaccine, three weeks apart, and the rest got dummy shots.
There were 77 cases of COVID-19 - 14 in the group that got the vaccine and the rest were in volunteers who received dummy shots. None in the vaccine group had moderate or severe disease, compared to 14 in the placebo group.
The vaccine was similarly effective against several variants including the one first detected in the U.K. that’s dominant in the U.S., and in high-risk populations including the elderly and people with other health problems.
Side effects were mostly mild - tenderness and pain at the injection site. There were no reports of unusual blood clots or heart problems, Erck said.
Novavax reported the results in a press release and plans to publish them in a medical journal, where it will be vetted by independent experts. The Maryland-based company previously released findings from smaller studies in Britain and South Africa.
Early yet on Side Effects, wait and see what happens.
In addition, if the test subjects felt sick after the second shot and went home and took Advil while the placebo group went to the bars, that could impact the 14 vs 63 split. The placebo should have some nasty additives that also sideline that lot.
Who are these people who volunteered to partake in this study, with the risk of getting a placebo, when they could've taken the Pfizer or Moderna drugs already on the market since December. I guess they don't call them dummy shots for nothing.